Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3
- PMID: 32098592
- DOI: 10.1161/CIRCRESAHA.119.315861
Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3
Erratum in
-
Correction to: Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3.Circ Res. 2022 Feb 4;130(3):e2. doi: 10.1161/RES.0000000000000532. Epub 2022 Feb 3. Circ Res. 2022. PMID: 35113665 No abstract available.
Abstract
Rationale: Excessive Ang II (angiotensin II) levels lead to a profibrotic and hypertrophic milieu that produces deleterious remodeling and dysfunction in hypertension-associated heart failure. Agents that disrupt Ang II-induced cardiac dysfunction may have clinical utility in the treatment of hypertension-associated heart failure.
Objective: We have examined the potential effect of celastrol-a bioactive compound derived from the Celastraceae family-on Ang II-induced cardiac dysfunction.
Methods and results: In rat primary cardiomyocytes and H9C2 (rat cardiomyocyte-like H9C2) cells, celastrol attenuates Ang II-induced cellular hypertrophy and fibrotic responses. Proteome microarrays, surface plasmon resonance, competitive binding assays, and molecular simulation were used to identify the molecular target of celastrol. Our data showed that celastrol directly binds to and inhibits STAT (signal transducer and activator of transcription)-3 phosphorylation and nuclear translocation. Functional tests demonstrated that the protection of celastrol is afforded through targeting STAT3. Overexpression of STAT3 dampens the effect of celastrol by partially rescuing STAT3 activity. Finally, we investigated the in vivo effect of celastrol treatment in mice challenged with Ang II and in the transverse aortic constriction model. We show that celastrol administration protected heart function in Ang II-challenged and transverse aortic constriction-challenged mice by inhibiting cardiac fibrosis and hypertrophy.
Conclusions: Our studies show that celastrol inhibits Ang II-induced cardiac dysfunction by inhibiting STAT3 activity.
Keywords: angiotensin II; heart failure; hypertension; molecular targeted therapy; signal transducer and activator of transcription 3.
Similar articles
-
OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes.Theranostics. 2023 Apr 17;13(7):2263-2280. doi: 10.7150/thno.83340. eCollection 2023. Theranostics. 2023. PMID: 37153745 Free PMC article.
-
The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H186-H200. doi: 10.1152/ajpheart.00531.2018. Epub 2018 Nov 2. Am J Physiol Heart Circ Physiol. 2019. PMID: 30387679 Free PMC article.
-
SENP1 Protects Against Pressure Overload-Induced Cardiac Remodeling and Dysfunction Via Inhibiting STAT3 Signaling.J Am Heart Assoc. 2022 Nov 15;11(22):e027004. doi: 10.1161/JAHA.122.027004. Epub 2022 Nov 12. J Am Heart Assoc. 2022. PMID: 36370010 Free PMC article.
-
Celastrol: The new dawn in the treatment of vascular remodeling diseases.Biomed Pharmacother. 2023 Feb;158:114177. doi: 10.1016/j.biopha.2022.114177. Epub 2023 Jan 3. Biomed Pharmacother. 2023. PMID: 36809293 Review.
-
Celastrol functions as an emerging manager of lipid metabolism: Mechanism and therapeutic potential.Biomed Pharmacother. 2023 Aug;164:114981. doi: 10.1016/j.biopha.2023.114981. Epub 2023 Jun 7. Biomed Pharmacother. 2023. PMID: 37285754 Review.
Cited by
-
Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway.Saudi Pharm J. 2020 Sep;28(9):1101-1111. doi: 10.1016/j.jsps.2020.07.011. Epub 2020 Aug 3. Saudi Pharm J. 2020. PMID: 32922141 Free PMC article.
-
Total or Near-total Thyroidectomy in treatment of Thyroid Cancer.Pak J Med Sci. 2022 Jul-Aug;38(6):1662-1667. doi: 10.12669/pjms.38.6.5765. Pak J Med Sci. 2022. PMID: 35991271 Free PMC article.
-
The Promising Therapeutic Potential of Celastrol for Fibrotic Diseases: A Systematic Literature Review on Its Mechanism.Cureus. 2023 Aug 28;15(8):e44269. doi: 10.7759/cureus.44269. eCollection 2023 Aug. Cureus. 2023. PMID: 37772226 Free PMC article. Review.
-
Isoproterenol induces MD2 activation by β-AR-cAMP-PKA-ROS signalling axis in cardiomyocytes and macrophages drives inflammatory heart failure.Acta Pharmacol Sin. 2024 Mar;45(3):531-544. doi: 10.1038/s41401-023-01179-3. Epub 2023 Nov 2. Acta Pharmacol Sin. 2024. PMID: 37919475 Free PMC article.
-
Interaction between neutrophil extracellular traps and cardiomyocytes contributes to atrial fibrillation progression.Signal Transduct Target Ther. 2023 Jul 26;8(1):279. doi: 10.1038/s41392-023-01497-2. Signal Transduct Target Ther. 2023. PMID: 37491321 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous